A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
Stopped Study closed by Protocol Review Monitoring Committee because of lack of accrual
Conditions
Interventions
Sponsor
University of Kansas
Collaborators